CZEN 003Alternative Names: CZEN-003
Latest Information Update: 13 Jul 2004
At a glance
- Originator Zengen
- Mechanism of Action Alpha-MSH stimulants; Immunosuppressants; Melanocortin receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Transplant rejection
Most Recent Events
- 13 Jul 2004 This compound is still in active development - BIO 2004 Annual International Convention (BIO-2004)
- 16 Dec 2002 Preclinical trials in Transplant rejection in USA (unspecified route)